RYSTIGGO®: The First and Only NICE-Reimbursed Targeted Therapy for MG

In April 2026, RYSTIGGO® (rozanolixizumab) achieved a significant milestone as the first and only targeted therapy for myasthenia gravis (MG) to be reimbursed by NICE. This reflects our ongoing commitment to advancing innovative, patient-focused treatments.

 

[UCBCares Pro][Rystiggo][Section 1][Image Text] [Image] In April 2026 we celebrated!

Proudly driven by our commitment to science and innovation

  • RYSTIGGO delivered rapid, significant, clinically meaningful improvements in daily living*1

  • RYSTIGGO targets FcRn to reduce IgG levels, including pathogenic gMG autoantibodies1-4

 

With over 4 decades of experience UCB has a strong heritage in neurology.

 

Do you know your local UCB specialist?

 

Fintepla®▼ (fenfluramine) is indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older.1

Rystiggo®▼ (rozanolixizumab) is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.

Rystiggo currently not reimbursed on the NHS in Scotland.

Zilbrysq®▼ (zilucoplan) is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

References:

1. RYSTIGGO® (rozanolixizumab) Summary of Product Characteristics.

2. Bril V, et al. Lancet Neurol. 2023;22(5):383–394.

3. Wolfe GI, et al. J Neurol Sci. 2021;430:118074.

4. Bril V, et al. J Neuromuscul Dis. 2025;12(2):218–230

 

*MycarinG was a randomised, double-blind, placebo-controlled, parallel-group, two-stage adaptive, phase 3 study that evaluated the safety and efficacy of RYSTIGGO in adults with anti-AChR or anti-MuSK antibody-positive gMG (N=200).2

GB-RZ-2600004 | September 2026